证券日报网讯12月12日晚间，迈得医疗发布公告称，公司拟以集中竞价交易方式回购股份，回购股份将 用于减少公司注册资本；回购股份金额不低于人民币2，000万元(含)，不超过人民币4，000万元(含)； 回购股份价格：不超过人民币24元/股(含)。回购股份期限：自公司股东会审议通过本次回购股份方案之 日起12个月内。 ...

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 迈得医疗(688310.SH)公告称，公司拟以集中竞价交易方式回购股份，回购金额不低于2000万元 （含），不超过4000万元（含），资金来源为首次公开发行股票超募资金或自有资金。回购价格不超过 24元/股（含），用于减少公司注册资本。回购期限自股东会审议通过之日起12个月内。 ...

广发证券股份有限公司 关于迈得医疗工业设备股份有限公司 使用部分超募资金以集中竞价交易方式回购股份 的核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐机构"）作为迈得 医疗工业设备股份有限公司（以下简称"迈得医疗"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 市公司募集资金监管规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交易所科创板股票上市规则》等法律法规的规定， 对迈得医疗使用部分超募资金以集中竞价交易方式回购股份的事项进行了审慎 核查，核查情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意迈得医疗工业设备股份有限公司首 次公开发行股票注册的批复》（证监许可〔2019〕2019 号），中国证券监督管理委 员会同意公司首次公开发行股票的注册申请。公司首次公开发行人民币普通股 （A 股）股票 2,090 万股，每股面值人民币 1.00 元，每股发行价格 24.79 元，募 集资金总额为人民币 51,811.10 万元，扣除发行费用人民币 6,075.96 万元（不含 税）后，募集资金净额为人 ...

迈得医疗(688310.SH)公告，公司拟以集中竞价交易方式回购股份，回购股份金额不低于2000万元(含)， 不超过4000万元(含)。回购股份价格不超过24元/股(含)。回购股份期限自公司股东会审议通过本次回购 股份方案之日起12个月内。 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2025-051 迈得医疗工业设备股份有限公司 关于以集中竞价交易方式回购股份的预案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 相关股东是否存在减持计划：公司董事、高级管理人员、控股股东、实际控制 人及其一致行动人、回购提议人、持股 5%以上股东在未来 3 个月、未来 6 个月暂 无减持公司股份的计划。若上述人员未来拟实施股份减持计划，公司将按相关规 定及时履行信息披露义务 ● 相关风险提示： 1、本次回购方案尚需提交公司股东会审议，存在股东会未审议通过回购股份方案 的风险； ● 回购股份金额：不低于人民币 2,000 万元（含），不超过人民币 4,000 万元（含） ● 回购股份资金来源：公司首次公开发行股票超募资金或自有资金 ● 回购股份用途：用于减少公司注册资本 ● 回购股份价格：不超过人民币 24 元/股（含）。该价格不高于公司董事会通过回 购股份决议前 30 个交易日公司股票交易均价的 150% ● 回购股份方式：集中竞价交易方式 ● ...

证券代码：688310 证券简称：迈得医疗 公告编号：2025-052 迈得医疗工业设备股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第二次临时股东会 召开日期时间：2025 年 12 月 30 日 13 点 30 分 召开地点：浙江省玉环市沙门镇滨港工业城迈得医疗工业设备股份有限公司 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 30 日 至2025 年 12 月 30 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 股东会召开日期：2025年12月30日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方 ...

迈得医疗工业设备股份有限公司 第五届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 迈得医疗工业设备股份有限公司（以下简称"公司"）第五届董事会第八次会 议（以下简称"本次会议"）于 2025 年 12 月 11 日以现场加通讯的方式在公司会 议室召开。本次会议的通知已于 2025 年 12 月 5 日以电子邮件方式送达全体董事。 本次会议由董事长林军华先生主持，应出席会议董事 8 人，实际出席会议董事 8 人。本次会议的召开符合《中华人民共和国公司法》等法律、行政法规以及《迈 得医疗工业设备股份有限公司章程》的相关规定。 二、董事会会议审议情况 经与会董事审议表决，通过了如下议案： (一)审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》 证券代码：688310 证券简称：迈得医疗 公告编号：2025-050 逐项表决结果如下： 1.01 回购股份的目的 基于对公司未来发展的信心和对公司价值的认可，为有效维护广大股东利益， 增强投资者信心，在综合考虑公司财务状况以 ...

智通财经APP讯，迈得医疗(688310.SH)公告，公司拟以集中竞价交易方式回购股份，回购股份金额不 低于2000万元(含)，不超过4000万元(含)。回购股份价格不超过24元/股(含)。回购股份期限自公司股东 会审议通过本次回购股份方案之日起12个月内。 ...

人民财讯12月12日电，迈得医疗(688310)12月12日公告，公司拟2000万元至4000万元回购股份用于减少 公司注册资本，回购价格不超过24元/股(含)。 ...